Understanding Urothelial Cancer through Tissue Collection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect and analyze tissue samples from patients with urothelial cancer to better understand the genetic and molecular changes associated with the disease. Participants will provide tumor tissue blocks, blood, urine, and saliva samples, which will be used to identify differences between normal and cancerous tissues. The research focuses on the potential development of targeted therapies and predictive biomarkers for urothelial cancer. Healthy volunteers will also contribute samples for comparison purposes.

Why it matters

Who can join: the full rules

* INCLUSION CRITERIA FOR UROTHELIAL CANCER PARTICIPANTS:
* Adults (\>= 18 years of age) with biopsy-proven or suspected urothelial cancer who require and are willing to undergo diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.
* ECOG performance status of 0-3.
* Must be willing and able to provide informed consent.

EXCLUSION CRITERIA:

* Subjects who are pregnant.
* Subjects co-morbidities preclude diagnostic or therapeutic intervention. Co-morbidities include:

  --Ongoing treatment for another non-skin malignancy.
* History of hepatitis B/C or HIV. Patients who are HIV positive are excluded from this study because treatment with immunomodulatory agents for immunosuppressed patients would affect sample analysis and skew the data.

ELIGIBILITY CRITERIA FOR HEALTHY VOLUNTEERS

INCLUSION CRITERIA:

-Adults (greater than or equal to 18 years of age) and able to give informed consent.

EXCLUSION CRITERIA:

* Subjects who are pregnant.
* Diagnosis of cancer requiring treatment other than minor resection of basal cell or squamous cell skin cancers.
* Heart, lung, kidney disease, or other medical conditions as per Principal Investigator discretion.
* History of acute or chronic hepatitis B/C or HIV infection. Patients who are HIV positive are excluded from this study because treatment with immunomodulatory agents for immunosuppressed patients would affect sample analysis and skew the data.
* Healthy volunteers who are family members with germline mutations.

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Raju R Chelluri, M.D. — National Cancer Institute (NCI)
• Study coordinator: Lidenys C O'Brien Gutierrez
• Email: lidenys.o'brien@nih.gov
• Phone: (240) 858-7481

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Acupuncture and Exercise for EV-Pembro–Induced Peripheral Neuropathy

  This study tests whether adding acupuncture to a gentle virtual exercise program helps reduce chemotherapy-induced nerve problems in bladder cancer patients taking EV and pembrolizumab.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07548476

• Datopotamab deruxtecan plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin for advanced or metastatic urothelial carcinoma

  This trial will test whether datopotamab deruxtecan with carboplatin or cisplatin works better than gemcitabine with carboplatin or cisplatin for people with advanced urothelial carcinoma who progressed during or after enfortumab vedotin plus pembrolizumab.

  Recruiting at 29 sites Phase 2/3 Daiichi Sankyo · Fullerton, California and 99 other locations · NCT07129993

• Understanding Urothelial and Rare Genitourinary Cancers

  This study is trying to learn more about urothelial and rare genitourinary cancers by gathering health information and samples from adults who have been diagnosed with these cancers.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04923178

• Sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial cancer

  This trial tests whether combining sacituzumab govitecan and enfortumab vedotin, with pembrolizumab in some patients, helps people with metastatic urothelial carcinoma who have progressed after platinum chemotherapy and PD‑1/PD‑L1 inhibitors.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT04724018

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.